MIG
ABUS icon

Mariner Investment Group’s Arbutus Biopharma ABUS Stock Holding History

Mariner Investment Group’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-89,800
Closed -$313K – 82
2016
Q2 		$313K Hold
89,800
– – 0.11% 107
2016
Q1 		$371K Sell
89,800
-63,333
-41% -$226K 0.1% 130
2015
Q4 		$681K Sell
153,133
-47,967
-24% -$263K 0.15% 138
2015
Q3 		$1.23M Hold
201,100
– – 0.25% 107
2015
Q2 		$2.38M Buy
201,100
+136,100
+209% +$2.07M 0.61% 58
2015
Q1 		$1.14M Buy
+65,000
New +$1.33M 0.3% 90

Other funds holding ABUS

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Mariner Investment Group's ABUS Position: Q3 2016 in Review

Mariner Investment Group sold out of Arbutus Biopharma (ABUS) in Q3 2016, closing a stake of 89,800 shares — an estimated $313K sold.

Mariner Investment Group first reported a position in ABUS in Q1 2015 and held it in 6 quarters. The position peaked at $2.38M in Q2 2015. 48 funds tracked by Wall St. Rank hold ABUS as of Q3 2016.

  • Mariner Investment Group reported no remaining Arbutus Biopharma position as of Q3 2016 after selling out during the quarter.
  • Mariner Investment Group sold 89,800 Arbutus Biopharma shares in Q3 2016, an estimated $313K.
  • Mariner Investment Group first reported a position in Arbutus Biopharma in Q1 2015 and held it in 6 quarters.
  • Mariner Investment Group's Arbutus Biopharma position peaked at $2.38M in Q2 2015.
  • 48 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2016.

Based on Mariner Investment Group's 13F filing for Q3 2016, filed 3 Nov 2016.